secwatch.observer — SEC 8-K summary
======================================

Issuer:     LABCORP HOLDINGS INC. (LH)
CIK:        0000920148
Form:       8-K
Filed at:   2023-01-05T23:59:59+00:00
Accession:  0000920148-23-000004
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Labcorp appoints Thomas Pike to lead Drug Development unit; will become CEO of spin-off company
--------------------------------------------------------------------------------

- Thomas Pike appointed President and CEO of Drug Development Clinical Development business, effective Jan 9, 2023.
- Upon planned spin-off (expected mid-2023), Pike will become CEO and Chairman of the independent publicly listed company.
- Paul Kirchgraber, current EVP and CEO of Drug Development, will depart after the spin-off; he continues leading Early Development, Central Laboratories, and Global Oncology.
- Labcorp to announce the new company's Board of Directors, including lead independent director, in coming months.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/920148/000092014823000004/0000920148-23-000004-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/920148/000092014823000004/lh-20230104.htm
  HTML page:      https://secwatch.observer/filing/0000920148-23-000004

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer